Deep brain stimulation in Lesch–Nyhan disease: outcomes from the patient’s perspective

JASPER E VISSER1,2 | ADAM C COTTON3 | DAVID J SCHRETLEN4 | JOCELYNE BLOCH5 | KRISTINA TEDROFF6 | GASTÓN SCHECHTMANN7 | DIANA RADU DJURFELDT8 | VICTORIA GONZALEZ9,10 | LAURA CIF10 | HYDER A JINNAH3

AIM To provide insight into outcome and long-term safety and efficacy of deep brain stimulation (DBS), from the perspective of individuals with Lesch–Nyhan disease (LND) and their families.

METHOD We used patient-centered outcome measures to assess long-term outcomes of DBS for 14 individuals (mean [SD] age 10y 10mo [5y 6mo], range 5–23y, all males) with LND, after an average duration of 5y 6mo (range 11mo–10y 5mo) after surgery. We compared these results with a comprehensive review of previously published cases.

RESULTS Patients and their families reported that DBS of the globus pallidus can be effective both for motor and behavioral disturbances in LND. However, outcome measures were often not significantly changed owing to substantial variability among individuals, and were overall less positive than in previous reports based on clinician assessments. In addition, there was an unexpectedly high rate of adverse events, tempering overall enthusiasm for the procedure.

INTERPRETATION Although DBS might be an effective treatment for LND, more research is needed to understand the reasons for response variability and the unusually high rates of adverse events before DBS can be recommended for these patients.

Lesch–Nyhan disease (LND) is caused by loss of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase, leading to hyperuricemia and a distinctive neurobehavioral phenotype.1,2 The movement disorder is dominated by dystonia, although chorea and spasticity are sometimes also present.3 Intellectual disability involves mainly executive tasks and attention.4 Behavioral abnormalities include oppositional and severe self-injurious behavior.5,6 Patients with partial enzyme deficiency (LND variants) do not exhibit self-injurious behavior, although the movement disorder and intellectual disability may occur with variable severity.7

Biochemical,8,9 histopathological,10 functional imaging,11,12 and experimental13–15 sources of evidence have indicated that the neurobehavioral abnormalities result from dysfunction of the basal ganglia, and especially the dopaminergic pathways.16 Existing treatments are only partly successful. Of note, levodopa does not provide a useful treatment, despite the profound dopamine deficiency in LND.17 Numerous other medications have been tried, with minimal success.1 Self-injury can often only be controlled by using protective straps to hold down the limbs. However, in recent years, deep brain stimulation (DBS) of the globus pallidus has been reported to reduce the severity of dystonia and reduce self-injurious behavior in LND, in several small studies.18–26

The current study provides a comprehensive review of all 12 published cases, followed by an assessment of outcomes from the perspective of 14 participants and their families.

METHOD For the literature review, the PubMed database was queried for articles that included the keywords ‘Lesch–Nyhan’ and ‘deep brain stimulation’ (last checked on 1st October 2020). From the results and reference lists therein, nine publications were identified, describing 12 unique cases. All were included here. Several large reviews have been

© 2021 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press. DOI: 10.1111/dmcn.14852
published where LND cases were summarized. These cases were not included here because insufficient clinical data were provided, and some of the cases reviewed were already published as case reports.

For the assessment of outcomes, 14 participants were identified through direct patient contact, patient support networks, or the Lesch–Nyhan Disease International Study Group. These participants came from France, the Netherlands, Sweden, Switzerland, or the USA. All received their procedures at centers with extensive experience with DBS. Data were assembled after review by the Medical Research Ethics Committee (Committee on Research Involving Human Subjects [CMO], Arnhem-Nijmegen, the Netherlands). Owing to the nature of the study, informed consent was not required. Early findings were previously reported for two of these cases, as included in the literature review.20,23,24

Primary caregivers were asked to discuss the procedure and its outcomes with the participant and other family members. Six individuals were not continuing with DBS at the time of reporting. The caregivers then completed a standardized questionnaire, which was adapted from a previous study of LND (Appendix S1, online supporting information).17 This questionnaire included 20 items using 9-point Likert-type scales.27 The first 18 questions assessed changes after DBS in six neurobehavioral domains (three questions per domain), including abnormal movements, self-injurious behavior, oppositional behavior, apathy, agitation, and depression. The answers were averaged to give a single result for each domain for each participant. Additional questions assessed overall opinions: the overall effect of DBS, whether they would consider DBS again in another patient with LND, and the participant’s own opinion about the DBS.

Data about adverse events were also methodically collected and tabulated. Finally, caregivers were asked to take into account all benefits and adverse events and give an overall assessment of the procedure, such as whether they would repeat it if needed, or recommend it to other individuals with LND.

Statistical analysis
Scores on the neurobehavioral domains and additional questions were analysed for their median (to assess the magnitude of changes) and interquartile range (IQR; as a measure of variability among respondents) using SPSS version 27.0 (IBM Corporation, Armonk, NY, USA) and Box-PlotR.28

RESULTS

What this paper adds
- Individuals with Lesch–Nyhan disease and their families report variable efficacy of deep brain stimulation.
- Long-term outcomes are associated with a high adverse event rate.

Participants with Lesch–Nyhan disease and their families report variable efficacy of deep brain stimulation.

For the assessment of outcomes, 14 participants were identified through direct patient contact, patient support networks, or the Lesch–Nyhan Disease International Study Group. These participants came from France, the Netherlands, Sweden, Switzerland, or the USA. All received their procedures at centers with extensive experience with DBS. Data were assembled after review by the Medical Research Ethics Committee (Committee on Research Involving Human Subjects [CMO], Arnhem-Nijmegen, the Netherlands). Owing to the nature of the study, informed consent was not required. Early findings were previously reported for two of these cases, as included in the literature review.20,23,24

Primary caregivers were asked to discuss the procedure and its outcomes with the participant and other family members. Six individuals were not continuing with DBS at the time of reporting. The caregivers then completed a standardized questionnaire, which was adapted from a previous study of LND (Appendix S1, online supporting information).17 This questionnaire included 20 items using 9-point Likert-type scales.27 The first 18 questions assessed changes after DBS in six neurobehavioral domains (three questions per domain), including abnormal movements, self-injurious behavior, oppositional behavior, apathy, agitation, and depression. The answers were averaged to give a single result for each domain for each participant. Additional questions assessed overall opinions: the overall effect of DBS, whether they would consider DBS again in another patient with LND, and the participant’s own opinion about the DBS.

Data about adverse events were also methodically collected and tabulated. Finally, caregivers were asked to take into account all benefits and adverse events and give an overall assessment of the procedure, such as whether they would repeat it if needed, or recommend it to other individuals with LND.

Statistical analysis
Scores on the neurobehavioral domains and additional questions were analysed for their median (to assess the magnitude of changes) and interquartile range (IQR; as a measure of variability among respondents) using SPSS version 27.0 (IBM Corporation, Armonk, NY, USA) and Box-PlotR.28

RESULTS

Literature search
Results from 12 unique LND cases previously reported are summarized in Table 1. The average reported age was 14 years 1 month (range 5y 5mo–28y). All individuals received bilateral stimulation of the globus pallidus. Improvements in dystonia were reported for all patients. Quantitative assessments of improvements in dystonia using the Burke-Marsden Dystonia Rating Scale29 scores were provided for eight cases, where there was a mean (SD) improvement of 19.7% (20.5%).

All reports also described improvements in self-injurious behavior. This behavior, which is normally a daily occurrence in LND,45 was reported to disappear in six cases, and became ‘rare’ in another. The remaining cases showed 50% to 80% reductions in the frequency and severity of difficult behaviors (including self-injurious behavior) using the Behavior Problems Inventory rating scale.30 Reported complications were addressed in only three papers, limited to hardware failures and infections in six participants.

Patient-centered outcomes
Outcomes for DBS surgery were collected from primary caretakers for 14 participants (Table 2). Thirteen participants were diagnosed with classic LND, on the basis of residual hypoxanthine-guanine phosphoribosyltransferase enzyme activity, HPRT1 gene analysis, and/or the full clinical phenotype with hyperuricemia, dystonia, and self-injurious behavior. One participant had dystonia with intellectual disability but did not express self-injurious behavior, and therefore met the criteria for being a variant without self-injury.7 Average age at the time of surgery was 10 years 10 months (range 5–23y). All patients underwent bilateral DBS of the globus pallidus. Seven had two electrodes implanted on each side (a total of four electrodes per case), to treat motor and behavioral aspects of the phenotype separately. The questionnaires were received on average 5 years 6 months after surgery (range 11mo–10y 5mo).

For the entire group of 14 participants, median rating scale scores were above 5 (suggesting improvements across most survey domains) (Fig. 1a), including abnormal movements (median 5.7, IQR 3.0), self-injurious behavior (median 6.0, IQR 2.7), oppositional behavior (median 6.3, IQR 3.3), apathy (median 5.2, IQR 1.0), and agitation (median 6.0, IQR 2.0). The median for depression indicated no change (median 5.0, IQR 2.0). For all of these domains, the median was consistently either 5 or very close to 5, suggesting that a clinically important change in any of these domains was lacking. Perhaps more importantly, the wide IQRs for most of the measures resulted from considerable variation in individual responses.

All patients but one experienced at least one adverse event (Table 2), either during the initial perioperative period or during follow-up. Six patients developed infections involving the equipment. Only one of these infections was attributed to persistent self-injurious behavior directed to the head. Five patients experienced hardware-related complications, such as broken wires. All but two patients required at least one additional surgical procedure.
Taking into account these benefits and adverse events, the overall impressions from caretakers were mixed (Fig. 1b). About half of the caregivers were positive about the overall effect of DBS in LND to a variable degree (median score 6.0, IQR 6.0), and only a similar proportion endorsed repeating the procedure (median 4.5, IQR 7.0). Also, about half of the patients were positive about the effects of DBS (median 6.0, IQR 5.0). Again, very wide IQRs indicated the absence of any consistent pattern, owing to extreme variability.

**DISCUSSION**

This study reviews reported effects of DBS in LND and compares them with patient-centered outcome measures to: (1) capture direct evidence of the perceived treatment benefit and (2) evaluate the utility of DBS for potential future patients.

The literature review including eight patients paints a very positive picture of the application of DBS in LND. Often, marked benefits in self-injurious behavior and at least partial benefits in the motor disorder were noted, and significant adverse events were infrequently reported. Our assessment of the outcomes of 14 patients from the viewpoint of the patients and their families provides a different perspective. In summary, perceived benefits varied considerably among responders and adverse events were common. Although many families gave an overall favorable assessment of the benefits of DBS, only about half would repeat the procedure.

The reasons for the variable overall impressions of DBS in LND by families cannot be conclusively determined from this study. However, a first possible explanation for the varied outcomes involves technical aspects of surgical implantation and programming. For example, the target site varied and several cases received two electrodes per side (four electrodes in total) in an attempt to specifically address both motor and non-motor features of LND by stimulating motor and limbic regions of the globus pallidus simultaneously. A review of the data (Fig. 1a,b), however, indicated no apparent differences among participants who had four versus two electrodes per side. All cases were operated and programmed at experienced centers, so it seems unlikely that lack of experience explains the variability. Another possible explanation for the variable motor

**Table 1: Summary of the literature for DBS in Lesch–Nyhan disease**

| Study          | Age at surgery (y) | Follow-up (y:mo) | Target(s) of DBS | Effect on dystonia | Effect on behavior | Complications       |
|----------------|--------------------|------------------|------------------|--------------------|--------------------|---------------------|
| Air et al.19   | 5                  | 1:0              | Bilateral GPi    | 16% improvement on BFMDRS | Decrease on BPI of 80% (frequency) and 75% (severity) | Lead fracture       |
| Deon et al.21  | 10                 | 2:6              | Bilateral GPi    | Dystonia decreased, comfort and function improved within 3mo | Self-injurious behavior disappeared | None                |
| Tambirajoo et al.26 | 11             | 1:10             | Bilateral posterior GPi | 1.6% improvement on BFMDRS movement scale, 0% on disability scale | Mild and temporary improvement | Migration of a lead infection |
| Pralong et al.23 | 12                | NR               | Bilateral anterior and posterior GPi | 'Significant decrease' of dystonic movements | Disappearance of many self-injurious behaviors within 3mo | NR                  |
| Pralong et al.23,24 | 12                | NR               | Bilateral anterior and posterior GPi | 'Significant decrease' of dystonic movements | Disappearance of many self-injurious behaviors within 3mo | NR                  |
| Tambirajoo et al.26 | 12                | 3:1              | Bilateral anterior and posterior GPi | 6.7% improvement on BFMDRS movement scale, 8.3% on disability scale | Improvement in frequency and severity of self-injurious behavior | Infection |
| Tambirajoo et al.26 | 13             | 8:1              | Bilateral anterior and posterior GPi | 3.8% improvement on BFMDRS movement scale, 6.3% on disability scale | Decrease on BPI of 68% (frequency) and 78% (severity) after 1y follow-up | Infection |
| Abel et al.18 | 15                 | 0:6              | Bilateral GPi    | Moderate improvement over course of several weeks | Self-injurious behavior became rare | Lead fracture and dislocations after fall |
| Cif et al.20   | 16                 | 2:4              | Bilateral anterior and posterior GPi | 40% improvement on BFMDRS, up to 28mo | Self-injurious behavior disappeared within several days | NR                  |
| Tambirajoo et al.26 | 16              | 12:0             | Bilateral anterior and posterior GPi | 1.3% improvement on BFMDRS movement scale, 4.0% on disability scale | Decrease on BPI of 53% (frequency) and 50% (severity) after 1y follow-up | Hardware issues |
| Taira et al.25  | 19                 | 2:0              | Bilateral GPi    | Gradual improvement, 33% reduction of BFMDRS | Self-injurious behavior disappeared after 3mo | NR                  |
| Piedimonte et al.22 | 28             | 5:0              | Bilateral GPi    | 55% decrease in BFMDRS | Self-injurious behavior disappeared within months | None                |

**DBS, deep brain stimulation; GPi, internal globus pallidus; BFMDRS, Burke–Fahn–Marsden Dystonia Rating Scale; BPI, Behavior Problems Inventory; NR, not reported.**
benefit is that the movement disorder in LND and its variants is variable and mixed.3,7 Dystonia is the dominant feature, but severity is variable among participants, and some cases also have spasticity and chorea. Although the magnitude of previously reported effects of DBS on the dystonia in LND seems to fall in the range that has been reported before for other dystonias,31,32 the other motor problems in LND that differ among participants may not respond to DBS of the internal globus pallidus and variably limit its effect. A third explanation for variable treatment effects may relate to the age of the participants at operation, which varied considerably. Presumably, treatment of the motor disorder at later ages and/or after longer disease duration may not be reversed as readily. Indeed, both younger age at time of surgery and shorter duration of symptoms were associated with better DBS outcomes,31,33 whereas longer duration of dystonia symptoms correlated negatively in previous studies.34

The reasons for the high frequencies of adverse events also remains uncertain. Even considering that DBS surgical site infections are more frequent in children compared with adults,19,35 the high rate of infections is of note, as LND is not associated with any known defect in the immune system. Also, the rate of hardware-related problems (50%) is substantially higher than previously reported in children (about 13–18%).19,35 Self-injurious behavior directed towards the equipment was reported in one patient only, and therefore does not appear to provide a good explanation for infections or equipment failures as has been postulated before.26 It is of note that, in this study, almost all patients underwent additional surgical interventions to treat complications or because of lack of effect. The serious consequence of hardware failures in patients with LND is clear, as the reoccurrence of severe dystonia32 and self-injurious behavior after sudden cessation of DBS may become medical emergencies.

Table 2: Demographic data and adverse events reported after DBS in each of the 14 cases for whom long-term assessments were collected

| Case | Clinical phenotype | Age at surgery (y) | Follow-up (y:mo) | Number of electrodes per side | Electrode location(s) | Problem(s) | Consequence | DBS still active at time of assessment |
|------|-------------------|--------------------|------------------|------------------------------|----------------------|------------|-------------|-------------------------------------|
| 1    | LND               | 7                  | 7:9              | 2                            | GPI, ventral pallidum | Broken wire | Replaced    | Yes                                 |
| 2    | LND               | 5                  | 3:2              | 1                            | GPI                  | Lead infection, broken wires | Electrode replaced | Yes (one side only) |
| 3    | LND               | 11                 | 4:9              | 2                            | GPI                  | Faulty equipment | Replaced | Yes (one side only) |
| 4    | LND               | 6                  | 3:3              | 2                            | GPI                  | Scalp infection spread to equipment | Removed one lead | No |
| 5    | LND               | 12                 | 5:8              | 2                            | GPI, anterior and posterolateral | Scalp infection due to self-injurious behavior causing cerebral abscess | Removed | No |
| 6    | LND               | 5                  | 7:6              | 1                            | GPI                  | Epilepsy, CSF leakage, local pain, infection, swallowing difficulties | Replaced, turned off | No |
| 7    | LND               | 13                 | 5:3              | 1                            | GPI                  | Skin erosion, wires exposed, infection, surgical removal | Removal | No |
| 8    | LND               | 12                 | 10:4             | 2                            | GPI, ventral pallidum | Delayed hardware failure, broken extension cable, infection | Replaced | Yes |
| 9    | LND               | 11                 | 8:11             | 2                            | GPI, ventral pallidum | Not reported | Two stimulator replacements | Yes |
| 10   | LND               | 7                  | 1:6              | 1                            | GPI                  | Seizure, edema around electrodes, stimulator pack improperly placed | Re-surgery to correct stimulator placement | Yes |
| 11   | LND               | 23                 | 9:9              | 1                            | GPI                  | None reported | Discontinued | No a |
| 12   | LND               | 21                 | 4:5              | 2                            | GPI                  | Uncontrolled movements, speech problems | Turned off | No |
| 13   | LND               | 11                 | 0:11             | 1                            | GPI                  | Confusion, extreme movements, speech difficulties | Yes |
| 14   | LND variant       | 7                  | 3:9              | 1                            | GPI                  | Abnormal sensations | Removed | No |

aOwing to lack of effect. DBS, deep brain stimulation; LND, Lesch–Nyhan disease; GPI, globus pallidus internal segment; CSF, cerebrospinal fluid.

To explain the discrepancy in the very positive outcomes reported in previous studies and the variable benefits with frequent adverse events in the current study, it is important to recognize that the literature on case reports is well-known for being biased towards favorable outcomes.36 Cases with lack of benefit or negative outcomes are less commonly reported, and negative follow-up reports are usually not published. In addition, the assessments of the investigators that publish the reports sometimes may not match the impressions of the patients or their families. Nevertheless, it has been shown that case reports have a significant influence on subsequent publications and
possibly on clinical practice as well. Therefore, it is crucial that anecdotal observations are tested in controlled clinical trials to guide future clinical practice.

Several limitations of this study should be acknowledged. One is recall bias. Although a certain degree of recall bias cannot be excluded, it must be noted that in children where the DBS is still on, the questionnaire addresses the current effects of the treatment, thus recall is not relevant. Moreover, most of the adverse events are less likely to be affected by recall bias, because most required additional procedures that could be verified in the medical records. Another limitation is the small number of participants, operated at different centers using different techniques. Although this factor may have contributed to variability in the results, it also shows a more representative result about what happens in the broader community, rather than at a single site. Third, the patient-centered outcome measures were obtained by giving the patient or family a questionnaire to fill out, or by reading the questionnaire to the patient and family as an aid to understanding the questions. The examiner was allowed to answer questions, but was not allowed to influence the result. This strategy may have influenced the result, although reports of adverse events are unlikely to be omitted or exaggerated by the presence of an examiner. Finally, the questionnaire used was not formally validated. Because LND is extremely rare with a very distinctive neurobehavioral phenotype, there are no formally validated clinician rating scales or patient-centered rating scales available. However, we followed standard recommended procedures when designing the questionnaire.

In summary, individuals with LND and their families report very variable outcomes in the influence of DBS on the behavior and motor disorder of LND. Some patients report good outcomes, whereas others do not. Adverse events requiring re-operation are common. Thus, although DBS might be an effective treatment for LND, more research is needed to fully understand the risk/benefit ratio for DBS in LND before DBS can be recommended for these patients. Ideally, these studies should be conducted by experienced teams prepared to deal with adverse events in this difficult population. In the meantime, the impressions of patients and families and the high risk of adverse events should be taken into consideration when counseling potential future patients and families about this treatment option.

ACKNOWLEDGEMENTS
This study was supported by a grant 916.12.167 (VENI) from the Nederlandse Organisatie voor Wetenschappelijk Onderzoek, fellowship F2014(1)-16 from the Hersenstichting, and a grant from LND Famiglie Italiane Onlus (JEV). Moreover, this study was supported in part by a grant to the Dystonia Coalition, which receives most of its support through National Institutes of Health grants NS065701 and NS116025 from the National Institutes of Neurological Disorders and Stroke, and TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (HAJ). The authors have stated that they had no interests that might be perceived as posing a conflict or bias.

SUPPORTING INFORMATION
The following additional material may be found online:
Appendix S1: Retrospective evaluation of deep brain stimulation for Lesch–Nyhan disease.
REFERENCES

1. Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scrivener CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill, 2001: 2317–70.

2. Lesch M, Nyhan WL. A familial disorder or uric acid metabolism and central nervous system function. Am J Med 1964; 36: 561–70.

3. Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006; 129: 1201–7.

4. Schretlen DJ, Ward J, Meyer SM, et al. Behavioral aspects of Lesch-Nyhan disease and its variants. Dev Med Child Neurol 2005; 47: 673–7.

5. Anderson LT, Ernst M. Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 2005; 35: 671–89.

6. Lloyd KG, Hornykiewicz O, Davidson L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981; 305: 1106–11.

7. Saito Y, Ito M, Hanaoka S, Ohama E, Akaboshi S, Takashima S. Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neurodegeneration 1999; 10: 66–71.

8. Gottle M, Prudente CN, Fu R, et al. Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease. Ann Neurol 2014; 76: 95–107.

9. Ernst M, Zanetkin AJ, Mistochnik JA, et al. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 1996; 334: 1568–72.

10. Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A 1996; 93: 5339–44.

11. Dunnett SB, Srinathssinghi DJ, Heavens R, Rogers DC, Knott MR. Monoamine deficiency in a transgenic (Hprt−/−) mouse model of Lesch-Nyhan syndrome. Brain Res 1989; 501: 401–6.

14. Egami K, Yotra S, Kasim S, et al. Basal ganglia dopamine loss due to defect in purine recycling. Neurobiol Dis 2007; 26: 396–407.

15. Jinnah HA, Wojick BE, Hunt M, et al. Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci 1994; 14: 1164–75.

16. Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev 2000; 32: 449–75.

17. Visser JE, Schretlen DJ, Bloem BR, Jinnah HA. Levodopa is not a useful treatment for Lesch-Nyhan disease. Mov Disord 2011; 26: 746–75.

18. Abel TJ, Dahn BD, Grossbach AJ, Jackson AW, Thomson T, Greenlee JD. Lateralized effect of pallidal stimulation on self-mutilation in Lesch-Nyhan disease. J Neurosurg Pediatr 2014; 14: 594–7.

19. Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: experience and technical pearls. J Neurosurg Pediatr 2011; 8: 566–74.

20. Cif L, Biolsi B, Gavarrini S, et al. Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch-Nyhan disease. Mov Disord 2007; 22: 2126–9.

21. Deon LL, Kalichman MA, Booth CL, Slavin KV, Gaebler-Spira DJ. Pallidal deep-brain stimulation associated with complete remission of self-injurious behaviors in a patient with Lesch-Nyhan syndrome: a case report. J Child Neurol 2012; 27: 117–20.

22. Piedmonte F, Andreani JC, Piedmonte L, Michelì F, Graff P, Bacaro V. Remarkable clinical improvement with bilateral globus pallidus internus deep brain stimulation in a case of Lesch-Nyhan disease: five-year follow-up. Neuroendocrinology 2015; 18: 118–22.

23. Pralong E, Pollo C, Villemure JG, Debatisse D. Oppositional defiant disorder in Lesch-Nyhan syndrome: Clinical outcome and connectivity analysis. Neuromodulation 2020. https://doi.org/10.1111/nen.13127. Online ahead of print.

24. Likert R. A technique for the measurement of attitudes. New York, NY: Science Press, 1932.

25. Hettinger K, Steinheuser J, Rappaport J, Tyers M. Box-PolR: a web tool for generation of box plots. Nat Methods 2014; 11: 121–2.

26. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73–7.

27. Jinnah HA, Matson JL, Dott L, Eshbensen AJ, Smalls Y. The Behaviour Problems Inventory: an instrument for the assessment of self-injury, stereotyped behavior, and aggression/destruction in individuals with development disabilities. J Autism Dev Disord 2001; 31: 577–88.

28. Moro E, LeKean C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. Eur J Neurol 2017; 24: 552–60.

29. Visser JE, Schretlen DJ, Harris JC, Jinnah HA. Lesch-Nyhan disease. In: Goldstein S, Reynolds CR, editors. The metabolic and molecular bases of inherited disorders. New York, NY: McGraw-Hill, 2001: 2537–70.

30. Visser JE, Schretlen DJ, Bloem BR, Jinnah HA. Levodopa is not a useful treatment for Lesch-Nyhan disease. Mov Disord 2011; 26: 746–75.

31. Abel TJ, Dahn BD, Grossbach AJ, Jackson AW, Thomson T, Greenlee JD. Lateralized effect of pallidal stimulation on self-mutilation in Lesch-Nyhan disease. J Neurosurg Pediatr 2014; 14: 594–7.

32. Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: experience and technical pearls. J Neurosurg Pediatr 2011; 8: 566–74.

33. Andrews C, Axles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit from deep brain stimulation? A meta-regression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1381–9.

34. Holloway KL, Baron MS, Brown R, Cifu DX, Carne W, Ramakrishnan V. Deep brain stimulation for dystonia: a meta-analysis. Neuromodulation 2006; 9: 253–61.

35. Kaminska M, Persides S, Lumsden DE, et al. Complications of Deep Brain Stimulation (DBS) for dystonia in children - The challenges and 10 year experience in a large paediatric cohort. Eur J Paediatr Neurol 2017; 21: 168–75.

36. Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes 2014; 7: 264.

37. Albrecht J, Meese A, Bigny M. Case reports and case series from Lancet had significant impact on medical literature. J Clin Epidemiol 2005; 58: 1227–32.